What they observed is that, in contrast to NLRP3 inflammasome blockade, both anti-PDL1 and combination treatment markedly increased the frequencies of tumor-infiltrating MDSCs without affecting the Treg population, indicating that the PDL1 blockade partly revoked the immune-stimulatory function of MCC950 in TME [93]. This evidence concerns the gene NLRP3 and neoplasm.